Antibiotics are the bedrock of modern medicine, and the world is running out of these magic bullets at ad ramatic pace. To date,a ntimicrobialr esistance (AMR) has been observed against all clinically used antibiotics. [1] The rapid and global emergenceo fA MR, which is forecastt oc ause as taggering 10 millionh uman deaths annually by the year 2050, [2] entails severe repercussions for public healthcare systems. At present, according to ar ecent extensive investigation, the healthcare burden of AMR in the European Economic Area (EEA) is already on ap ar with the combined effect of influenza, HIV,a nd tuberculosis,a nd about 33 000 people in the EEA die as ac onsequenceo fA MR every year. [3] Likewise, AMR is estimated to cause costs of billions of euros for the European economy. [4] To make things worse, the industry's drug-discoveryp ipeline for antibioticsi sa lmost empty.I ti sh ence of pressing need to develop new antibiotics that target unexploited pathways and that are robustt ot he development of resistance mechanisms.
This has led to an increased interest in unconventional agents such as naturally occurring antimicrobial peptides,a gainst which bacteria have enormousd ifficulty in building up effective resistance mechanisms. Here we focus on as pecial class of powerful antimicrobial peptidest hat specifically target lipid II, the precursor of the bacterial peptidoglycan( PGN) network. [5] 2. Lipid II, the Achilles' Heel of Bacteria Every bacterium is surroundedb yaP GN network, ap rotective hull that is essential for its survival. To ensure cell viability, growth, and division, PGN biosynthesis must be tightly regulated. The PGN network is composed of strandso fa lternating N-acetylmuramic acid and N-acetylglucosamine (MurNAc-GlcNAc) disaccharides linked through pentapeptide bridges. The PGN is synthesized from its plasma-membrane-anchored precursor lipid II, which carries one complete PGN subunit linked through au nique pyrophosphate group to aC 55 polyisoprenoid moiety.
However,l ipid II exists only in very low copy numbers, andi t is constantly recycled through the so-called lipid II cyclet o ensure efficient PGN synthesis ( Figure 1A ). This means that any drug that sequesters lipid II, and thereby stalls the PGN synthesis, is ap otential antibiotic. [5a, 6] In the case of Gram-positive bacteria the plasma membrane is readily accessible from the outside, so certain peptidesc an exploit this weak spot and specifically bind lipid II at its pyrophosphate group. [7] This is a unique mode of action that kills even highly resistants uperbugs such as methicillin-resistant Staphylococcus aureus (MRSA) at nanomolarc oncentrations, and against which resistance is difficult to acquire because the lipid II structure is highly conserved and the pyrophosphate group is even deemedi rreplaceable. [5a] In addition, because human cells do not produce lipid II, it is at arget with al ow risk of unwanted The alarming rise of antimicrobialr esistance (AMR) imposes severe burdens on healthcare systems and the economy worldwide, urgentlyc alling for the development of new antibiotics. Antimicrobial peptides could be ideal templates for nextgeneration antibiotics, due to their low propensity to cause resistance. An especiallyp romisingb rancho fa ntimicrobial peptides target lipid II, the precursor of the bacterial peptidoglycan network. To develop these peptidesi nto clinically applicable compounds, detailedi nformation on their pharmacologi-cally relevantm odes of action is of criticali mportance. Here we review the binding modes of as election of peptides that target lipid II and highlight shortcomings in our molecular understanding that, at least partly,r elate to the widespread use of artificial membrane mimics for structurals tudies of membrane-active antibiotics. In particular,w ith the example of the antimicrobial peptiden isin, we showcaseh ow the native cellular membrane environment can be critical for understanding of the physiologically relevant binding mode.
toxicity. Peptidest hat bind lipid II could hence be promising templates for next-generation antibiotics;h owever,d etailed information on their modes of action is critically required in order to develop them into clinically applicable drugs.
Peptide Antibiotics that Bind Lipid II
Below we discuss structurals tudies on as election of representative peptides that bind lipid II, including plectasin, [8] teixobactin, [9] tridecaptin A1, [10] and nisin. [11] These peptides were chosen either because of their unique modes of action or because of their popularity.U nfortunately,d ue to the limited format of this minireview,w ew ill not discusst he modes of action of other antimicrobials that bind lipid II, such as plusbacin A3, [12] ramoplanin, [13] nukacin ISK-1, [14] or vancomycina nd its derivatives, [15] most of which were recently reviewed elsewhere. [6] Most of the antibiotics that bind lipid II kill bacteria by sequestering it, thereby blockingt he lipid II cycle. Furthermore,s ome of the reviewed peptides such as teixobactin are also known to bind precursors of wall teichoic acids or other PGN precursors, whereas peptides such as the lantibiotic nisin [11] additionally recruit lipid II to form pores through the plasma membrane ( Figure 1B ). Such dual-or multi-killing mechanisms render peptides that bind lipid II even less susceptible to causing AMR. In Section 4w es how that ap hysiologically relevantmembrane environment can be indispensable for understanding of the modes of action of peptides that bind lipid II.
Plectasin
Defensins are am ajor class of host-defense peptides, found in almosta ll eukaryotes. They are small (3-5 kDa) and contain three to five disulfide bonds. It was recently discovered that certain CSab defensins specifically target lipid II. [16] These CSab defensins, definedb yacommon a-helix-b-sheet fold, act by sequestering lipid II to block PGN synthesis. The best-known example is plectasin, from the fungus Pseudoplectania nigrella (Figure 2A ). [8] Plectasin tightly (K D = 1.8 10 À7 m)b inds lipid II in a1 :1 stoichiometry. [16] The activity spectrum of plectasin is broad and includes medically important Gram-positive pathogens. [8] In addition, plectasin is stable and can be produced in large quantities. Altogether,p lectasin is an excellent lead for rational drug design,a nd the plectasin triple mutant NZ2114 (D9N, M13L, Q14R) is currentlyi nc linical trials. [17] Our structuralu nderstanding of the binding mode of plectasin is based on as olution NMR study in dodecylphosphocholine (DPC) micelles with at runcated, water-soluble lipid II construct. On titration with micelles containing lipid II, as mall number of plectasin residues (F2, C4,A 31, G33, C37, and K38) showed larger chemical shift perturbations (CSPs). [16] AC SPbased HADDOCK [18] model suggestst hat the backbone amide protons of the Nterminus and the C-terminal b-strand form hydrogen bonds with the lipid II pyrophosphate and the pentapeptide ( Figure 2A ). That the pentapeptide is part of the complex interface agrees with the fact that the enzymatic amidation of the g-d-Glu residue in the lipid II pentapeptide decreases the antimicrobialefficiency of plectasin. [19] However,m any aspects of plectasin's binding mode remain unclear.F or example, the stark influence of the lipid II GlcNAc sugar on the binding affinity of plectasin [16] cannotb ee xplained by the micelle model,i nw hich GlcNAc is far from the Jo¼oM edeiros-Silva obtained his Master's degree in biochemistry from NOVAUniversity Lisbon, working on sugar-protein interactions and the synthesis of G-quadruplex ligands. Currently he is aP h.D. student in the lab. of Markus Weingarth at Utrecht University.H is work involves the development of strategies to study complex systems such as membrane-active antibiotics and ion channels in their native environment by solid-state NMR.
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Markus Weingarth did his Ph.D. at École normale supØrieure (Paris) in the laboratory of Geoffrey Bodenhausen, working on solid-state NMR methods, followed by apostdoc with Marc Baldus at Utrecht University,w orking on NMR methods for membrane proteins. Honors include aFEBS Distinguished Young Investigator Award and an NWO VIDI Award. He now is Assistant Professor,and his research deals with ion channels and bioactive peptides with afocus on antibiotics. (Figure 2A ), whereas the conserved side chain of H18 ( Figure 2C ), which is assumedt ob ec ritically involved in binding of lipid II, was not detectable in NMR experiments in micelles. [16] Moreover,the model does not provide as tructurale xplanationo fw hy the triple mutantN Z2114 exhibits af avorable activity over WT plectasin. Furthermore, the 1:1binding stoichiometry was determined with awater-soluble version of lipid II, and this might notn ecessarilyr eflect the binding to membrane-imbedded lipid II. In addition, the mo-lecular function of the remarkable anionic stretch( 9-DEDD-12) of plectasin remains unknown. Interestingly,a lthough CSab defensins such as eurocin [20] or copsin [21] share ac ommon fold with plectasin, they exhibit only low sequence homology and marked differences in the lengths of certain loops ( Figure 2B , C). It is unknown whether or not theses tructural differences modulate the binding mode to lipid II or if CSab defensins share as imilar binding motif.
Teixobactin
Te ixobactin ( Figure 3) is an 11-residue macrocyclic depsipeptide that is non-ribosomally produced by the soil bacterium Eleftheriat errae. Ah ighly promising compound for the development of antibiotics with excellent potency against multidrug-resistant Gram-positive bacteria, it exhibits favorable pharmacokinetics and activity in mousem odels. [9] Te ixobactin binds lipid II and the cell-wall teichoic acid precursor undecaprenyl-PP-GlcNAc (lipid III)b ya na sy et uncertain mechanism. [22] Initial studies established that the pyrophosphate group is part of teixobactin's binding motif. Most notably,ar ecent solidstate NMR (ssNMR) study in DPC micellesb yt he Lewandowski lab. provided more detailed structural insights into teixobactin's mode of action ( Figure 3 ). [23] That study suggests that teixobactin forms larger aggregates upon binding to lipid II;t his was also supported by ar ecent X-ray study in aqueous solution. [24] Intriguingly,s uch higher-order aggregates of peptide· lipid II complexes could be of considerable importance under physiological conditions because lipid II is assumed to be predominately concentrated in specific cell membrane regions. [5b, 6b] In the bound state, the C-terminal macrocyclic part of teixobactin presumably complexes lipid II, whereas the N-terminal residues,w hicha re disordered in the unbounds tate, [25] adopt a b-strand structure involved in peptidea ggregation. Such a binding mode is in line with recent long MD simulations of the teixobactin·lipid II complex in membranes. [26] Interestingly,t he solid-state NMR study also strongly suggestst hat the pentapeptideo rt he sugar moieties of lipid II play ac ritical role for the binding mode and aggregation of teixobactin. Currently, extensive efforts are being undertaken to simplify the complex structurea nd to lower the financial constraints on the development of teixobactin-based drugs. In the process, it was surprisingly revealed that the unusual enduracididine residuea tp osition 10 can be replaced by branched l-amino acids without any adverseeffect on antimicrobial activity. [22] 
Tridecaptin A 1
Tridecaptins are linear,n on-ribosomally synthesized lipopeptides isolated from Bacillus and Paenbacillus speciest hat bind lipid II and have the rare qualityo fs howinga ctivity against Gram-negative bacterial strains including Escherichia coli, Klebsiella pneumoniae,a nd Acinetobacter baumannii. This activity profile is especially noteworthy because of the strong need for new antibiotics against Gram-negative bacteria, as illustrated by the "Priority Pathogen List for Research and Development on Antibiotics" of the World Health Organization( WHO). [27] The archetypical representative is tridecaptin A 1 (Figure 4A) , which disrupts the proton-motive force, presumably by forming small protonp ores acrosst he bacterial plasma membrane, as recently showninane legant study by the Vederas lab. [10] Tridecaptin A 1 crossest he outer membrane of aG ram-negative bacterium by specificallyi nteractingw ith ac hiral target of lipopolysaccharide (LPS). The N-terminal lipid tail, however,i s not necessary for crossing the outer membrane,a lthoughi ts presence is criticalf or the antimicrobial activity of tridecapti-nA 1 .N otably,t ridecaptin A 1 displays selective targeting of the lipid II of Gram-negative bacteria;t his lipid II variant possesses a meso-diaminopimelic acid (mDAP) residue-as opposed to a lysine residue-at the 3-position in the pentapeptide (Figure 4B ,C). [10] The mDAP residue is presumably directly involved in complex formation,g iven that the activity of tridecaptin A 1 against Gram-positive bacteria is strongly reduced. Indeed, solution NMR experiments in DPC micelles showed that tridecaptin A 1 targets the lipid II pentapeptide, with no binding to the pyrophosphate group being observed.
Whereas unbound tridecaptin A 1 adopts an elongated structure, in the bound state it wraps around lipid II in ap rocess stabilized by a p-stacking interaction between residues d-Trp5 and l-Ph9. The importance of this stacking interaction was recently corroboratedb yc hemical engineering. Here, good antimicrobial activity was observed after covalent bridgingo fr esidues 5a nd 9, forming ac yclic construct. [28] Furthermore, the NMR structure suggests an interaction between the g-amino group of d-Dab8,w hich is essential for antimicrobial activity of tridecaptins,a nd the e-carboxylate group of the mDAP residue in lipid II. However,b ecause the small proton pores that tridecaptin A 1 presumably forms couldn ot be observedi nD PC micelles,i nsights into the physiological mode of action most www.chembiochem.org likely require al iposomal setting. This is as imilar situation as for nisin, discussed in the next section.
Towards the Native Mode of Action
Until recently,q uantitative structurald atao np eptide-lipid II interactions had exclusivelyb een obtained in nonphysiological media such as DMSO or micelles.S uch artificial media, as highlighted by recent publications, [29] are strongly compromised in their capacity to mimic lipid membranes, cand estabilize secondary structures, promote disorder, and generally perturb the native folding and topology of membrane-embedded or associated biomolecules. As we elaborate with af ew selected examples, many aspects of the modes of action of drugs that bind lipid II have thus far evadeddeeper structural understanding. This lack of information might, at least partially,r elate to the use of artificial membrane mimics. In the case of tridecaptin A 1 ,f or example, it seems highly likely that the small pores that represent the physiological binding mode cannot be observedi nm icelles. Using the lantibiotic nisin as as howcase, we have recently,f or the first time, explored quantitative peptide-lipid II interactions at high resolution in lipid membranes and in native cellular bacterial membranes. Our study demonstrated that lipid membranes are essential for the physiologically relevant binding mode of nisin, and very likely also for the native binding modes of many other antimicrobials that target lipid II.
The membrane environment modulates the nisin pore
Lantibiotics are heavily modified peptides, characterized by thioether rings. [6a] The class A(I) lantibiotic nisin, produced by Lactococcusl actis,i st he most widely studied peptide that binds lipid II ( Figure 5A ). Nisin is globally used as ap reservativei n the food industry and has ar ecognized potential for clinical use, [31] including against drug-resistantb acterial strains and biofilms.A sd iscovered in ap ioneering study by Breukink et al.,n isin kills bacteria at nanomolar concentrations through au nique mechanism called targeted pore formation, [11] for which eight nisin and four lipid II moleculesa re assumed to form al ethalh ole that spans the plasma membrane (Figure 5B ). [6a] Althought his mechanism was discovered > 15 years ago, the pore structure is still unknown. The only structuralinformation came from as olutionN MR study in DMSO,w hich yielded the famous" pyrophosphate cage", in which the amide backbone protons of the thioether rings Aa nd Bc oordinate to the lipid II pyrophosphate group ( Figure 5C ). However,b yu sing an advanced solid-state NMR approach in lipid membranes, we have recently shown that the nisin·lipid II complex as determined in DMSO corresponds to an on-native state. We observed large andg lobal chemical shift perturbations between nisin bound to lipid II in DMSO and in membranes;t his demonstrates am ajor conformational changei nl ipid membranes, including in the pyrophosphate cage ( Figure 5D ). [30] Importantly,w ep erformedt his study with modern 1 H-detected solid-state NMR, [32] which was critical for direct investigation of the backbonea mide protons of nisin that coordinate lipid II.
High-resolution NMR in native bacterial cell membranes
Althoughr econstitutedl iposomes represent an important step towardsp hysiologically relevant media, they fall short of the stunningc omplexity of cell membranes that host ap lethora of different lipid and protein types.F urthermore, the variations in the chemical structure of lipid II that are presenti nd ifferent bacterials trains can decisively influence the binding modes of some antimicrobials. [33] In principle, ssNMR enables structural studies of biomolecules directly in native cellular membranes. However,b ecause of the heterogeneity of cellular membranes and the low native copy numbers of lipid II, such studies critically require the use of advanced highly sensitives sNMRm ethods such as 1 H-detection [32] andd ynamic nuclear polarization (DNP). [34] 1 Hd etection, driven by the advent of very high magic-angle spinningf requencies,m akes use of the direct detection of protonn uclei. Of all biological nuclei, protons have the highest gyromagnetic ratio, and the higher this physicalc onstant the highert he NMR signals ensitivity.M oreover, 1 Hd etection is Figure 5 . A) Nisin featuresf ive thioether rings, of which rings Aa nd Ba re critical for binding lipidII. B) Nisinand lipid II form ad efinedpore that spans the bacterial plasma membrane. C) The pyrophosphate cage structure as determined in DMSO. [7] The thioether rings Aa nd Bo fn isin are annotated. D) Overlay of 2D NH spectrao fthe nisin·lipid II complexi nD OPC (blue)a nd in DMSO (red).T he ssNMRs pectrum was measured at 950 MHz( 1 Hf requency) and 60 kHz magic-angle spinning. The solution NMRs pectrum in DMSO was publishedp reviously. [7] (A) and (D) reproduced from ref. [30] .C opyright: 2018, the authors. compatible with physiological buffer conditions and temperatures, and enables direct access to amide protons,w hich generally seem immediately involved in the binding of lipid II. In DNP experiments, conducted at cryogenic temperatures,t he system is doped with small radicals. The gyromagnetic ratio of an electron is more than 600 times highert han for a proton, and this can translate into enormous signal enhancements. Here, through the use of microwave irradiation, spin polarization is transferred from the radicals to the system of interest such as ap eptide antibiotic,a nd this is then followed by aN MR experiment with improveds ensitivity.
Using ac ombination of both NMR methods, we succeeded in investigating the nisin·lipid II pore complex directlyi nc ellular membranes of Micrococcus flavus ( Figure 6A )w ith as little as 5-10 nmol of nisin. This study showed that 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG)l iposomes are very good mimics for the nisin·lipid II pore and enable physiologically relevant insights to be obtained. Intriguingly,t his study,s upported by 1 H/ 2 He xchange experiments, [35] also revealed that the so-called hinge region ( Figure 5A )a nd the linker between thio rings Ba nd Ca re both plastic and enable nisin to adapt to the complexity of cellular membranes (Figure 6C,D ) . Thisi sa ni mportant finding because these linker regionsa re pharmaceutical hotspots, and mutations in these regions were indeeds hown to modulate nisin's activity in as train-specific manner ( Figure 6E ). [36] These insights were only possible in native cellularm embranes.
Summary and Outlook
Drugs that bind lipid II have aroused considerable interest, due to their potencya nd their robustness to the development of AMR. In order to use these promisingc ompounds for the design of next-generation antibiotics, ad etailed understanding of the pharmacologically relevant binding modes is essential. In recent years as mall number of structural studies have considerably advanced our comprehension of drugst hat bind lipid II. However,t hese studies have predominantly been performed in membrane mimics such as DMSO and micelles,a nd the extent to which such artificial mediae nable native binding modes is uncertain. In ordert ou nderstand the pharmacologically relevant binding modes, it is therefore essential to investigate membrane-active drugs under physiological conditions. Here, ssNMR [37] and the advent of highly sensitives ignal enhancement and detection methods bode well for performance of structural studies directly in cellular membranes and, in the future, even with whole cells. [38] Such cellular experiments could be of particularv alue for investigation of higher-order complexes such as pores or aggregates,w hich seem to be more commona mong drugs that bind lipid II, and which are of special interestg iven that lipid II seems to be Figure 6 . A) Comparison of 1 H-detected2 DN Hs pectrao fn isin bound to lipid II in cellular M. flavus membranes (magenta) and in DOPC (cyan). The gray spectrums howsn isin nonspecifically bound to liposomes in the absenceo fl ipid II. B) 13 Cs pectra of nisin bound to lipid II in M. flavus membranes with (magenta)a nd without(black) DNP enhancement. C) The hinge domain is plasticand broadenso ut under DNP conditions with a1 00 Ks ample temperature (orange). This is even morepronounced in cellularm embranes (magenta). Upper panel:zoom into residue A*23, adjacentt ot he hinge. Lower panel:zoom into M21 of the hinge. D) Membrane arrangement of the nisin·lipid II topology from ssNMR. Plastic residues are highlighted with red circles.Residues that showed 1 H/ 2 He xchangea re colored in blue andalign the pore lumen. The Cterminus is dynamically disordered. The Aa nd Br ings (in magenta) interact with the pyrophosphate group. E) Linker residues (in red) are pharmaceutical hotspots that enable improvement of nisin'sactivity uponmutation.These residues were all identifieda si mportant for nisin's cellular adaptability by cellulars sNMR. [30] Figurereproducedfrom ref. [30] .Copyright: 2018, the authors.
ChemBioChem 2019, 20,1731 -1738 www.chembiochem.org 2019 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim more concentrated inc ertain regionso ft he cell membrane. [5b, 6b] We can envision that such cellular structural studies could be used to understand and break bacterial drug-resistance mechanisms, or to optimize antibiotics' selectivity against specific bacterial strains. The latter is of particulari mportance in light of our growingu nderstanding of the human microbiota. [39] Altogether, such truly native studies of membrane-active antibioticss hould become an indispensable tool to sharpen our weapons against drug-resistant bacteria.
